A Phase II, Single-Arm Study of Ribociclib (LEE011), Everolimus, and Letrozole, in Patients with Advanced or Recurrent Endometrial Carcinoma
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and ribociclib can help to control recurrent (has returned after treatment) or progressive endometrial cancer. The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 08/18/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: